Enter your email address below and subscribe to our newsletter

Patient Education

Share your love

An eye on how patients perceive their retinal diseases

(Image credit: ©De Visu/AdobeStock) A recent study identified a large disconnect between patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) who are treated with intravitreal injections. The survey results highlighted the significant treatment burden experienced by…

First time results of VOY-101 for geographic atrophy

Omer Trivizki, MD, MBA, at the 2025 ASRS meeting Omer Trivizki, MD, MBA, Deputy Chair working in Tel Aviv Medical Center presented, “First time results of VOY-101, a novel, complement-modulating gene therapy for geographic atrophy.” This presentation was given at…

First patients dosed in JC02-88 study

(Image credit: ©Alernon77/AdobeStock) jCyte recently announced the dosing of the first patients enrolled in the JC02-88 study for the evaluation of famzeretcel (jCell; jCyte) for the treatment of retinitis pigmentosa (RP).1 Famzeretcel consists of allogeneic retinal progenitor cells (RPCs) administered…

Peptide Eye Drops Offer Hope for Dry AMD

Researchers from the Natural Product Drug Development Center at the Korea Institute of Science and Technology (KIST), led by Dr. Moon-Hyeong Seo, have developed an innovative therapeutic agent for dry age-related macular degeneration (AMD) in the form of peptide-based eye…

Mental Health Gaps Affect Diabetic Eye Screenings

A research team from Great Britain has identified several key barriers that prevent patients with diabetes from attending annual diabetic eye screenings. These include mental health challenges, lack of awareness about diabetic eye screening (DES), and transportation difficulties. The study,…

MicroPulse TLT Proven Effective for Glaucoma

Iridex Corporation, a global leader in laser-based medical systems for glaucoma and retinal disease treatment, has announced the publication of a groundbreaking peer-reviewed study in Ophthalmology Therapy. The study provides compelling evidence of the long-term safety and efficacy of MicroPulse…

Galimedix Begins Phase 2 Trial for GAL-101 in Dry AMD

Galimedix Therapeutics has announced the initiation of a phase 2 clinical study called eDREAM (NCT06659549), evaluating the efficacy and safety of GAL-101 eye drops in patients with dry age-related macular degeneration (AMD) and geographic atrophy (GA). About the Phase 2…

Stay informed and not overwhelmed, subscribe now!